TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 4005392
Drug: Sustained-release tablets
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release tablets containing 40 mg isosorbide dinitrate
Study: 4005392
Drug: Reference standard-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference standard-release tablets containing 20 mg isosorbide dinitrate
Study: 27243900
Drug: PrEP adherence
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PrEP adherence (pill count coverage)
Study: 20929609
Drug: Salmeterol/Fluticasone Propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/Fluticasone Propionate (SFC) 50 μg/100 μg b.i.d.
Study: 20929609
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate (FP) 200 μg b.i.d.
Study: 1386374
Drug: GnRHa with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa with norethindrone 5 then 10 mg daily
Study: 6693601
Drug: Self-application of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-application of topical medication
Study: 6693601
Drug: Cream vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream vs ointment
Study: 31627089
Drug: Triple fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple fixed-dose combination (TFC) therapy of perindopril/indapamide/amlodipine
Study: 31627089
Drug: Triple free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple free combination therapy (FCT) including ACEI/diuretic/CCB
Study: 26155765
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg, twice daily during 12 weeks of chemotherapy
Study: 26155765
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily during 12 weeks of chemotherapy
Study: 24646102
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU vitamin D3 daily (group B)
Study: 24646102
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (200 mg ferrous sulfate and 600 mg calcium daily, group A)
Study: 23302671
Drug: Policosanol, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol, 20 mg/d, n = 36
Study: 23302671
Drug: Placebo, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two tablets/d, n = 36
Study: 17697309
Drug: G-TIVA-TEA (Total
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-TIVA-TEA (Total Intravenous Anesthesia with Thoracic Epidural Anaesthesia)
Study: 17697309
Drug: G-TIVA (Total
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-TIVA (Total Intravenous Anesthesia without Thoracic Epidural Anaesthesia)
Study: 17697309
Drug: G-ISO-TEA (Isoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-ISO-TEA (Isoflurane Anaesthesia with Thoracic Epidural Anaesthesia)
Study: 17697309
Drug: G-ISO (Isoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-ISO (Isoflurane Anaesthesia without Thoracic Epidural Anaesthesia)
Study: 11510868
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Fluoxetine-HCI (Prozac, Ely Lilly Belgium)
Study: 7802236
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg.kg‐1 at T1 of 10% (n = 10)
Study: 7802236
Drug: Edrophonium 1
Normalized name: edrophonium 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 1 mg.kg‐1 at T1 of 25% (n = 10)
Study: 25567713
Drug: Amoxicillin (or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (or clindamycin)
Study: 18252814
Drug: Standard parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard parenteral and enteral nutrition (control group)
Study: 12604409
Drug: Glutamine-enriched parenteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched parenteral nutrition (20 g) from day +1 after aPBSCT in study 1
Study: 12604409
Drug: Glutamine-enriched parenteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched parenteral nutrition (13.46 g) from day +1 after aPBSCT in study 2
Study: 12604409
Drug: Glutamine-enriched parenteral
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine-enriched parenteral nutrition
Study: 10694002
Drug: MenD (bivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenD (bivalent meningococcal A + C diphtheria‐toxoid‐conjugated vaccine)
Study: 10694002
Drug: MenPS (meningococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenPS (meningococcal A + C polysaccharide vaccine)
Study: 10694002
Drug: H. influenzae
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. influenzae type b‐tetanus toxoid‐conjugated vaccine
Study: 9169958
Drug: Pulse-dosing (PD)
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse-dosing (PD) of doxepin (250 mg every 6 days)
Study: 9169958
Drug: Conventional (CONV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional (CONV) application of doxepin (increasing dosages until day 7, then 250 mg on other days)
Study: 31520284
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment over 6 months
Study: 26996043
Drug: Rosehip Oil
Normalized name: ROSA CANINA FRUIT OIL 95 g in 100 g TOPICAL LIQUID [ROSEHIP Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosehip Oil (ARM, Repavar®) applied twice daily from the beginning of treatment
Study: 26996043
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with different skin treatments
Study: 22225620
Drug: Pateclizumab 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pateclizumab 3.0 mg/kg SC (MAD group)
Study: 22225620
Drug: Pateclizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pateclizumab (all doses)
Study: 16505415
Drug: Ad5CMV‐p53 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5CMV‐p53 monotherapy (1 x 10(9) to 1 x 10(11) plaque‐forming units)
Study: 16505415
Drug: Ad5CMV‐p53 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5CMV‐p53 in combination with intravenous cisplatin (80 mg/m2)
Study: 15136392
Drug: Antibiotic discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic discontinuation policy
Study: 15136392
Drug: Conventional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotic management
Study: 8646440
Drug: In-patient multidisciplinary
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient multidisciplinary treatment for 11 days followed by standard out-patient care (n = 39)
Study: 6848334
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of nifedipine
Study: 28302532
Drug: Intranasal Tear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Tear Neurostimulator (ITN)
Study: 26687550
Drug: Average number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Average number of medications
Study: 23451764
Drug: TU-100 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU-100 2.5 g t.d.s.
Study: 23451764
Drug: TU-100 5
Normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TU-100 5 g t.d.s.
Study: 12558620
Drug: Topical paromomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical paromomycin
Study: 8840744
Drug: Comprehensive pharmacy
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comprehensive pharmacy services including monthly blood pressure and heart rate assessments, counseling on lifestyle modifications and drug therapy
Study: 1378641
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of induction chemotherapy with Bleomycin, Methotrexate and Hydroxyurea before definitive external radiotherapy (60 Gy)
Study: 1378641
Drug: 4 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of chemotherapy administered between the 20‐ and the 40‐Gy doses
Study: 29047128
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg fentanyl + 10 ml bupivacaine 0.08% (F20 group)
Study: 29047128
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg fentanyl + 10 ml bupivacaine 0.08% (F50 group)
Study: 29047128
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg fentanyl + 10 ml bupivacaine 0.08% (F100 group)
Study: 29047128
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg fentanyl (F20 group)
Study: 29047128
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg fentanyl (F50 group)
Study: 29047128
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg fentanyl (F100 group)
Study: 27282865
Drug: liraglutide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide (0.6 mg for 7 days, 1.2 mg for 7 days, 1.8 mg for 3 days)
Study: 25155593
Drug: AVI-6002 (0.005,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI-6002 (0.005, 0.05, 0.5, 1.5, 3, and 4.5 mg/kg per component)
Study: 25155593
Drug: AVI-6003 (0.005,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI-6003 (0.005, 0.05, 0.5, 1.5, 3, and 4.5 mg/kg per component)
Study: 25155593
Drug: Placebo (4:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4:1 ratio with active study drug)
Study: 23271778
Drug: Radical prostatectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical prostatectomy and hormonal treatments
Study: 10910479
Drug: Rocuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.2 mg/kg
Study: 9627910
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamins (beta-carotene, 6 mg; vitamin C, 120 mg; and vitamin E, 30 mg) and trace elements (zinc, 20 mg; and selenium, 100 micrograms)
Study: 9627910
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vitamins and trace elements
Study: 2896635
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of active medication (Session 4)
Study: 28545518
Drug: Lipid-lowering usual
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering usual care (including maximally tolerated statin therapy, with options to add ezetimibe, fenofibrate, omega-3 fatty acids, or nicotinic acid)
Study: 28545518
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg Q2W (for those with non-HDL-C ≥100 mg/dl at week 8)
Study: 17165363
Drug: g-hydroxybutyrate (GHB,
Approvals — FDA: no, EMA: no, PMDA: no
Description: g-hydroxybutyrate (GHB, 50 mg/kg of body weight t.i.d)
Study: 17165363
Drug: naltrexone (NTX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: naltrexone (NTX, 50 mg/day)
Study: 17165363
Drug: disulfiram (DSF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: disulfiram (DSF, 200 mg/day)
Study: 10768307
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) as adjunctive therapy; mean dosage 9 mg/kg/day
Study: 3802724
Drug: 250 mumol
Normalized name: AGALSIDASE ALFA 600 umol ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mumol of lithium carbonate given orally in single doses
Study: 3802724
Drug: 250 mumol
Normalized name: AGALSIDASE ALFA 600 umol ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mumol of lithium carbonate given orally in continuous doses
Study: 3802724
Drug: 100 mmol
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mmol of oral NaCl added to the diet of volunteers receiving lithium
Study: 30311061
Drug: Phytotherapeutic drug
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytotherapeutic drug (baicalin 190 mg; bromelain 50 mg; escin 30 mg)
Study: 28668226
Drug: Maternal supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal supplemental oxygen administration
Study: 28668226
Drug: No maternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maternal supplemental oxygen administration
Study: 19713429
Drug: NSAID infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID infusion (administered via microdialysis catheter into the vastus lateralis muscle before, during, and for 4.5 h after exercise)
Study: 19713429
Drug: NSAID infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID infusion
Study: 17430734
Drug: Supplement containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement containing soy isoflavones and Actaea racemosa L. (n = 60)
Study: 11580778
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate (50 mg kg(‐1) body weight)
Study: 8083910
Drug: Early parenteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early parenteral nutrition (TPN)
Study: 4533701
Drug: Intra-amniotic administration
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic administration of PGF2alpha
Study: 4533701
Drug: 15-methyl-PGF2alpha (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-methyl-PGF2alpha (2.5 mg intra-amniotic injection)
Study: 4533701
Drug: 16,16-dimethyl-PGE2 (repeated
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16,16-dimethyl-PGE2 (repeated oral administration)
Study: 42628
Drug: Chlordiazepoxide lactam
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlordiazepoxide lactam (5 mg)
Study: 29072415
Drug: Cognitive-behavioral stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral stress management group therapy for 18 hours
Study: 23921361
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment with intrauterine insemination (IUI)
Study: 19213976
Drug: Paroxetine controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine controlled-release (12.5 mg-50 mg/day)
Study: 17694662
Drug: Monitoring body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring body temperature without treatment
Study: 12478881
Drug: Ketoconazole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (up to 800 mg/day)
Study: 9809930
Drug: Calcium antagonist-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist-based strategy (verapamil)
Study: 9809930
Drug: Beta-blocker/diuretic-based strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker/diuretic-based strategy (atenolol/hydrochlorothiazide)
Study: 2576365
Drug: picumast dihydrochloride
Normalized name: Levocetirizine Dihydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: picumast dihydrochloride 1 mg twice daily for 6 weeks
Study: 30523908
Drug: Zinc-lactate-containing mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-lactate-containing mouthwash (10 ml/30 s)
Study: 30523908
Drug: Zinc-lactate-containing mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-lactate-containing mouthwash (15 ml/60 s)
Study: 30523908
Drug: Rinse without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rinse without zinc-lactate (3 droplets/10 ml tap water/30 s)
Study: 30523908
Drug: Tap water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tap water (10 ml/30 s)
Study: 25351498
Drug: Prednisolone (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (60 mg daily in tapering doses)
Study: 23804278
Drug: Oral clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clopidogrel (CLO) 75 mg
Study: 23804278
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (ASA) 81 mg
Study: 12723101
Drug: Oral-B CrossAction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral-B CrossAction Toothbrush
Study: 9869369
Drug: Pilocarpine (P)
Normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pilocarpine (P) administered by the ocular route
Study: 2589233
Drug: Dexamethasone (DXM)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DXM) 24 mg in 5 doses
Study: 2589233
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 1 mg/kg as a single dose
Study: 29944516
Drug: Preoperative intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative intravenous methylprednisolone 125 mg (group MP)
Study: 29944516
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline intravenous (group C)
Study: 27522037
Drug: Bitter tastant
Normalized name: BITTER MELON
DrugBank: Momordica charantia fruit (DB14265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitter tastant mixture (0.88 mg SOA, 0.088 mg QE, 0.22 mg RF)
Study: 22820896
Drug: Orlistat 20
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 20 mg
Study: 22820896
Drug: Orlistat 40
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 40 mg
Study: 22820896
Drug: Orlistat (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (various doses)
Study: 17692727
Drug: RNF (Rebif®
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNF (Rebif® New Formulation, 44 μg/0.5 mL SC tiw)
Study: 17692727
Drug: EVIDENCE study
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EVIDENCE study (approved formulation of IFN‐β1a, identical regimen)
Study: 16332661
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (12 mg Fe/d for 6 d/wk for 35 wk)
Study: 16332661
Drug: Electrolytic iron
Normalized name: electrolytic iron
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electrolytic iron (12 mg Fe/d for 6 d/wk for 35 wk)
Study: 16332661
Drug: Hydrogen-reduced iron
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-reduced iron (12 mg Fe/d for 6 d/wk for 35 wk)
Study: 383171
Drug: radio-chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: radio-chemotherapy combined with the methanol extraction residue of BCG (MER)
Study: 383171
Drug: radio-chemotherapy
Normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
Approvals — FDA: no, EMA: no, PMDA: no
Description: radio-chemotherapy
Study: 25998755
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection with sodium hyaluronate
Study: 19542104
Drug: Alfentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 15 microg kg(‐1) 90 s before propofol injection
Study: 19542104
Drug: Lidocaine 0.1%
Normalized name: Capsaicin/Lidocaine 0.1%-4% Topical application Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 0.1% premixed with propofol 3 mg kg(‐1) over 15 s
Study: 19542104
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alfentanil and lidocaine
Study: 12114412
Drug: Bryostatin 1
Normalized name: Bryostatin 1
DrugBank: Bryostatin 1 (DB11752)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bryostatin 1 (50 microg/m(2)) administered as a 24‐h continuous infusion on days 1 and 11 before and after high-dose 1-beta-D-arabinofuranosylcytosine (HiDAC; 1.5 g/m(2) every 12 h x 4 on days 2 and 3, and 9 and 10)
Study: 9690979
Drug: fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxetine 20 mg/day
Study: 2031969
Drug: Intensive consolidation
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive consolidation chemotherapy (SIC)
Study: 30171041
Drug: Exercise 1×/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise 1×/week for 6 weeks during active treatment
Study: 24729398
Drug: golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab 50 mg from weeks 0 to 48
Study: 24729398
Drug: placebo from
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo from weeks 0 to 20 followed by golimumab 50 mg from weeks 24 to 48
Study: 20858280
Drug: Albendazole (anthelmintic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (anthelmintic treatment)
Study: 16819768
Drug: verapamil 2.5
Normalized name: verapamil 2.5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 2.5 mg and molsidomine 1 mg
Study: 16819768
Drug: verapamil 2.5
Normalized name: verapamil 2.5 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 2.5 mg
Study: 16819768
Drug: verapamil 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 5 mg
Study: 16819768
Drug: molsidomine 1
Normalized name: molsidomine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: molsidomine 1 mg
Study: 12814763
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (500 mg of elemental calcium as carbonate and 400 IU of vitamin D bid for 12 months)
Study: 10658002
Drug: Essential amino
Normalized name: Essential amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential amino acids and carbohydrate drink (6 g essential amino acids, 35 g sucrose)
Study: 8138866
Drug: Blind, placebo‐controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind, placebo‐controlled medication trial (MT)
Study: 19716319
Drug: Epalrestat 150
Normalized name: Epalrestat
DrugBank: Epalrestat (DB15293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epalrestat 150 mg/day (EP group)
Study: 15808118
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg/day orally for 4 weeks
Study: 8173242
Drug: VDT work
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VDT work (less than 6 hours daily)